Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 9,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Assess Screening for Diabetic Retinopathy Using Retinal Camera in Family Medicine Clinic

NCT03828890
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Screening eye exam using Optos technology
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Not applicable Interventional

SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence

NCT04080180
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Contingency Management, Brief Motivational Interviewing + Substance Free Activities + Mindfulness
Behavioral
Lead sponsor
Karen Derefinko, PhD
Other
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Not applicable Interventional Results available

Post-bypass Prophylactic IVIG in Infants and Neonates

NCT02043379
View directory record Official record
Conditions
Hypogammaglobulinemia, Congenital Heart Disease
Interventions
IVIG, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 6 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 24, 2026, 2:14 AM EDT
Terminated Early Phase 1 Interventional

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

NCT01537861
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Filgrastim, Bortezomib, Carfilzomib, Dexamethasone, Cyclophosphamide, Thalidomide, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated

NCT05045183
View directory record Official record
Conditions
Wound Healing
Interventions
SoC Adhesive Bandage, Antibiotic Ointment, Antiseptic Wash, Hydrocolloid Pad
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 24, 2026, 2:14 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).

NCT02834975
View directory record Official record
Conditions
Fallopian Tube Cancer, Peritoneum Cancer, Epithelial Ovarian Cancer
Interventions
Pembrolizumab, Paclitaxel, Carboplatin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 24, 2026, 2:14 AM EDT
Terminated Phase 2 Interventional Results available

GVAX vs. Placebo for MDS/AML After Allo HSCT

NCT01773395
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions
GVAX, Placebo Vaccine, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan, Fludarabine, Tacrolimus, Methotrexate
Biological · Procedure · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 24, 2026, 2:14 AM EDT
Terminated Phase 3 Interventional Results available

The Hemophilia Inhibitor Eradication Trial

NCT04303572
View directory record Official record
Conditions
Hemophilia A With Inhibitor
Interventions
Eloctate ITI, Emicizumab
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 24, 2026, 2:14 AM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

NCT04418895
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
Other · Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 24, 2026, 2:14 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

NCT03160339
View directory record Official record
Conditions
Adenoviral Infection
Interventions
PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Cincinnati, Ohio • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate Lower Extremity Sleeve and Pump Device to Treat Hemiparesis

NCT05535257
View directory record Official record
Conditions
Upper Extremity Weakness, Stroke
Interventions
Sequential Compression Device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Saint Johns, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 24, 2026, 2:14 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone

NCT03639857
View directory record Official record
Conditions
Cutaneous Lupus
Interventions
532nm laser, 1064nm laser, Topical corticosteroid
Device · Drug
Lead sponsor
David Weinstein
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 24, 2026, 2:14 AM EDT
Terminated Phase 2 Interventional Results available

Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS

NCT03495713
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Nivolumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers

NCT01587313
View directory record Official record
Conditions
Healthy
Interventions
Isosorbide dinitrate / hydralazine capsules
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM

NCT00905060
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
HSPPC-96, Temozolomide, Standard Surgical Resection
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 24, 2026, 2:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Stop, Focus, Plan, and Change: Predicting Parent and Child Responses to a Brief, Telehealth Parent Training

NCT06505980
View directory record Official record
Conditions
Behavioral Problem, Irritable Mood, Parenting, Stress
Interventions
Brief Behavioral Parenting Program
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 5 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

NCT05626803
View directory record Official record
Conditions
Norovirus Infections
Interventions
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose, Placebo
Drug
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 80 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Long Beach, California • Lenexa, Kansas • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

NCT03308942
View directory record Official record
Conditions
Neoplasms
Interventions
Niraparib, Pembrolizumab, TSR-042 (Dostarlimab)
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Whittier, Alaska • Port Saint Lucie, Florida • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 24, 2026, 2:14 AM EDT
Active, not recruiting Not applicable Interventional

Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm

NCT06411418
View directory record Official record
Conditions
Intracranial Aneurysms
Interventions
Pipeline™ Flex Embolization Device with Shield Technology™
Device
Lead sponsor
Jacobs institute
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 24, 2026, 2:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

NICU Utilization of Remote Voice Technology to Improve mateRnal Experience (NURTURE)

NCT07214597
View directory record Official record
Conditions
Postpartum Depression (PPD), Self-Efficacy, Parental Anxiety, Engagement, Patient, Usability, Length of Stay
Interventions
VoiceLove mobile phone application
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

Perifosine in Treating Patients With Advanced Soft Tissue Sarcoma

NCT00064324
View directory record Official record
Conditions
Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
perifosine, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study

NCT00462423
View directory record Official record
Conditions
Metastatic Malignant Melanoma
Interventions
Avastin, Abraxane
Drug
Lead sponsor
Lynn E. Spitler, MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
San Francisco, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

NCT02683746
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lyophilized albiglutide DCC pen injector, Lyophilized albiglutide DCC pen injector matching placebo, Albiglutide liquid auto-injector, Albiglutide liquid auto-injector matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
70
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 24, 2026, 2:14 AM EDT
Completed Not applicable Interventional Results available

AXIOS Stent & Delivery System Study

NCT01419769
View directory record Official record
Conditions
Pancreatic Pseudocyst(s)
Interventions
AXIOS Stent & Delivery System
Device
Lead sponsor
Xlumena, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
San Francisco, California • Aurora, Colorado • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Oct 24, 2026, 2:14 AM EDT